Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTP-543 in Moderate to Severe Alopecia Areata
NCT04518995Phase 3Completed
- Sponsor
- Concert Pharmaceuticals
- Start
- Nov 2020
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of deuruxolitinib in alopecia areata, sponsored by Concert Pharmaceuticals. Started Nov 2020; status: completed.
02
Drugs
deuruxolitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT04518995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04518995.